Bevacizumab and temsirolimus: which benefit in the therapeutic management of patients with a metastatic renal cell carcinoma?

被引：0
作者：
Ravaud, A. [1 ,2 ]
Bernhard, J. -C. [3 ]
Ferriere, J. -M. [2 ,3 ]
机构：
[1] CHU Bordeaux, Med Oncol Serv, Hop St Andre, F-33075 Bordeaux, France
[2] Univ Bordeaux 2, F-33076 Bordeaux, France
[3] CHU Bordeaux, Hop Pellegrin, F-33000 Bordeaux, France
来源：
ONCOLOGIE | 2008年 / 10卷 / 11期
关键词：
Bevacizumab; Temsirolimus; Anti-angiogenic therapy; mTOR inhibitor; Metastatic renal cell carcinoma;
D O I：
10.1007/s10269-008-0964-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Bevacizumab and temsirolimus are two drugs recently developed and integrated in the first-line therapeutic management of patients with advanced ormetastatic renal cell carcinoma. Bevacizumab, a monoclonal antibody directed against circulating VEGF, has shown a significant benefit in progression-free survival during a randomized phase III trial in comparison to alpha interferon (5.4 to 10.2 months; HR: 0.63; P < 0.0001). Temsirolimus, an agent that inhibits the mTOR pathway, has shown a significant gain in overall survival, in a randomized phase III trial conducted in a population of patients with poor risk feature of metastatic renal cell carcinoma, compared to alpha interferon (7.3 to 10.9 months; HR: 0.73; P < 0.0069).
引用
收藏
页码：653 / 656
页数：4
相关论文
共 21 条
[1]  
ATKINS MB, 2004, J CLIN ONCOL, V24, pS18
[2]   Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features [J].
Bellmunt, J. ;
Szczylik, C. ;
Feingold, J. ;
Strahs, A. ;
Berkenblit, A. .
ANNALS OF ONCOLOGY, 2008, 19 (08) :1387-1392
[3]  
Bukowski RM, 2007, J CLIN ONCOL, V25, P4536, DOI 10.1200/JCO.2007.11.5154
[4]   Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus [J].
Duran, I. ;
Siu, L. L. ;
Oza, A. M. ;
Chung, T. -B. ;
Sturgeon, J. ;
Townsley, C. A. ;
Pond, G. R. ;
Seymour, L. ;
Niroumand, M. .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (12) :1875-1880
[5]  
DUTCHER JP, 2007, J CLIN ONCOL, V25
[6]   Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].
Escudier, Bernard ;
Pluzanska, Anna ;
Koralewski, Piotr ;
Ravaud, Alain ;
Bracarda, Sergio ;
Szczylik, Cezary ;
Chevreau, Christine ;
Filipek, Marek ;
Melichar, Bohuslav ;
Bajetta, Emilio ;
Gorbunova, Vera ;
Bay, Jacques-Olivier ;
Bodrogi, Istvan ;
Jagiello-Gruszfeld, Agnieszka ;
Moore, Nicola .
LANCET, 2007, 370 (9605) :2103-2111
[7]   Sorafenib in advanced clear-cell renal-cell carcinoma [J].
Escudier, Bernard ;
Eisen, Tim ;
Stadler, Walter M. ;
Szczylik, Cezary ;
Oudard, Stephane ;
Siebels, Michael ;
Negrier, Sylvie ;
Chevreau, Christine ;
Solska, Ewa ;
Desai, Apurva A. ;
Rolland, Frederic ;
Demkow, Tomasz ;
Hutson, Thomas E. ;
Gore, Martin ;
Freeman, Scott ;
Schwartz, Brian ;
Shan, Minghua ;
Simantov, Ronit ;
Bukowski, Ronald M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134
[8]  
Feldman DR, 2007, J CLIN ONCOL, V25
[9]  
Figlin RA, 2008, J CLIN ONCOL, V26
[10]   Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer [J].
Gordon, MS ;
Margolin, K ;
Talpaz, M ;
Sledge, GW ;
Holmgren, E ;
Benjamin, R ;
Stalter, S ;
Shak, S ;
Adelman, DC .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :843-850
123